|
|
Article: Cancer Research UK Approves OXiGENE's Tumor-starving Compound OXi4503 for Final Pre-clinical Studies.
- Article from:
- Business Wire
- Article date:
- May 27, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
BIOWIRE2K
WATERTOWN, Mass.--(BUSINESS WIRE)--May 27, 2003
Evaluation of new vascular targeting agent in humans to follow pre-clinical tests
Study published today in Anticancer Research highlights significant potency of anti-tumor compound
OXiGENE, Inc. (NASDAQ:OXGN)(XSSE:OXGN) and Cancer Research UK, one of the world's largest cancer research organizations, today announced they are collaborating on the final pre-clinical development of one of OXiGENE's most advanced vascular targeting agents (VTAs), OXi4503. Under an agreement between the parties, Cancer Research UK will complete ...